Phosphodiesterase 4B isoform 2 (PDE4B2)

Phosphodiesterase 4B isoform 2 (PDE4B2) is a short isoform of the PDE4B enzyme, distinguished by its unique regulatory domains, specifically containing only the UCR2 domain[1]. PDE4B2 predominates specifically in human neutrophils and monocytes, playing a specialized role in controlling immune and inflammatory reactions by degrading cyclic AMP (cAMP) in a tightly regulated manner[2]. This isoform serves as a molecular “off-switch” for cAMP signaling, impacting cell function, differentiation, and proliferation. Aberrant PDE4B2 expression or function is implicated in pathogenic inflammation and tumorigenesis, making PDE4B2 inhibition a promising therapeutic strategy in a range of immune and malignant diseases[4]. Selective targeting of PDE4B2 with specific inhibitors is under investigation for treating various inflammatory and neoplastic disorders[4][6].

Other names

PDE4B2Type 4 cyclic AMP-specific phosphodiesterase isoform B2cAMP-specific phosphodiesterase 4B2

Inhibition of cAMP breakdown: Drugs act as PDE4B inhibitors, increasing intracellular cAMP, which dampens inflammatory responses and alters downstream signaling (especially via the PKA pathway). Suppression of inflammatory cell activation: Enhanced cAMP dampens cytokine production and immune cell reactivity.